SUMMARY Faeces (n = 1319) were examined over three months for the presence of non-sorbitol fermenting, verotoxin producing Escherichia coli (serotype 0157). Seven isolates were found, four from patients with bloodstained diarrhoea and three from patients with no evidence of blood in the faeces. Screening of all faecal samples with specific 0157 antiserum for non-sorbitol fermenting organisms and agglutination was an important adjunct to clinical and microscopic findings and helped detect cases of verotoxin producing E coli which might otherwise have been missed.
SUMMARY Faeces (n = 1319) were examined over three months for the presence of non-sorbitol fermenting, verotoxin producing Escherichia coli (serotype 0157). Seven isolates were found, four from patients with bloodstained diarrhoea and three from patients with no evidence of blood in the faeces. Screening of all faecal samples with specific 0157 antiserum for non-sorbitol fermenting organisms and agglutination was an important adjunct to clinical and microscopic findings and helped detect cases of verotoxin producing E coli which might otherwise have been missed. showed that some strains of serotypes 026, 0111, and 0128 produced a toxin that was active against Vero cells (African Green monkey) in tissue culture. The cytopathic effect was distinct from that produced by the heat labile toxin. The occurrence of verotoxin producing strains of E coli has now been widely reported.2 O'Brien et al reported that verotoxin is closely related to the Shiga toxin produced by strains of Shigella dysenteriae type 1.5 Scotland et al discovered two distinct verotoxins (VT1 and VT2) when performing neutralisation tests with antiserum to Shiga toxin. 6 Two clinical conditions are associated with verotoxin producing E coli; haemolytic uraemic syndrome and haemorrhagic colitis. Haemolytic uraemic syndrome, a severe illness of young children, is characterised by microangiopathic haemolytic anaemia, thrombocytopenia, and renal failure. It June and 16 September 1986 were included in the trial. They were inoculated on to MacConkey agar, which contained 1% sorbitol in place of lactose (Oxoid Ltd, CM813). After overnight incubation at 37°C NSF colonies were identified by multipoint inoculation. Isolates were tested for oxidase; Voges-Proskauer reaction; adonitol, inositol, lactose, raffinose and rhamnose fermentation; hydrogen sulphide, indole and urease production; citrate utilisation; tryptophan deamination and anaerobic fermentation of glucose. Lysine, ornithine, and arginine decarboxylation were performed using a modified version of the method of Falkow,22 using bromothymol blue in place of bromocresol purple, and incubation in an anaerobic atmosphere instead of oil overlay. A sorbitol fermentation test was also included to act as confirmation of the primary fermentation result from the sorbitolMacConkey medium. All organisms were inoculated on to cystine lactose electrolyte deficient agar as a check for purity. After incubation results were entered into a microcomputer to identify the organism using a profile index developed in the laboratory.
Those isolates identified as E coli were tested for agglutination with experimental 0157 antiserum (Wellcome Diagnostics) using slide and tube agglutination techniques. For the slide test, colonies from purity plates were emulsified in phosphate buffered saline (PBS) pH 74. A loopful of antiserum was applied and mixed and the slide was rocked and examined for agglutination. The tube test was performed in microtitre trays. Isolates were inoculated into brain heart infusion broth (Difco Laboratories, 0037-17) and incubated for 18 hours at 37°C. Cultures were then boiled for 30 minutes and diluted 1/100 to give an organism suspension of about 107 cfu/ml. Twofold dilutions of 0157 antiserum were made in PBS, from 1/4 to 1/256, to give a volume of 100 p1 in each well.
The organism suspension was added to give a final volume of 200 Ild and a final range of antiserum dilutions from 1/8 to 1/512. The tray was incubated for four hours at 37'C, followed by 4'C overnight, and examined for a carpet of agglutination. A known E coli serotype 0157 (kindly supplied by the Enteric Pathogens Reference Laboratory, Central Public Health Laboratory, Colindale, London) was included in each batch. Isolates identified as E coli 0157 were confirmed as E coli using the API 20E strip (API Products Ltd).
All NSF E coli isolates were stored at -700C. Verotoxin production was tested by a modification of the method of Karmalia et al.2' The isolates were inoculated into brain heart infusion broth and 81 incubated for 18 hours at 37°C. The growth was harvested by centrifugation and washed twice with PBS. The supernatant fluid was discarded and the organisms were treated with polymixin B 0-1 mg/ml (Sigma Chemicals Ltd) for 30 minutes at 370Cv After centrifugation the supernatant fluid was inoculated on to a monolayer of Vero cells (prepared in microtitre trays) and incubated for three days at 37°C. The cells were examined daily for cytopathic effects. A known verotoxin producing E coli (kindly supplied as above) was included in each batch.
During the trial, those faeces from which E coli 0157 had been isolated were stored at -20°C. These faeces were examined as a batch for the presence of verotoxin. Thawed faeces were suspended in an equal volume of PBS and centrifuged at 14000 g for two minutes (Eppendorf Microfuge). The supernatant fluid was sterilised by filtration (0-22 gm, Millipore) and inoculated on to a monolayer of Vero cells. The cells were incubated for three days at 37°C and examined daily for cytopathic effects.
Clinical details supplied by practitioners were retrospectively subjected to text analysis using the Microseek database search facility on the laboratory's minicomputer (ITL-PHLS Microlab). This listed those patients with bloodstained diarrhoea. Using the same facility, laboratory results were analysed for those samples where microscopy had shown the presence of red blood cells.
Results
During the trial, 1319 faecal samples were examined. Two hundred and eleven NSF organisms were isolated, giving a faecal carriage rate of 16%. Of these, 86 (41 %) were E coli. On further examination 21 of 86 (24%) E coli proved to be sorbitol fermenters. Table I lists the remaining NSF organisms.
Sixty five NSF E coli isolates were tested for agglutination with the 0157 antiserum, for verotoxin production, and for lysine and ornithine decarboxylation. Six strains agglutinated in both the slide and tube tests. These six strains produced a cytopathic effect on Vero cells after 24 hours' incubation. One of the remaining isolates also produced verotoxin; this isolate was retested and found to agglutinate with the 0157 antiserum. These seven isolates were subsequently confirmed as verotoxin producing E coli 0157 by the Enteric Pathogens Reference Laboratory, Colindale, London. Of the seven strains of verotoxin producing E coli 0157, six produced both lysine and ornithine decarboxylase. One failed to produce either ( 24 There has, however, been one published report ofa sorbitol fermenting isolate of verotoxin producing E coli 0157 from a patient with haemorrhagic colitis.'8 We have also seen a similar strain, isolated outside the period of the trial. This was from a patient with bloodstained diarrhoea in whom E coli 0157 was suspected (unpublished data). These results suggest that non-sorbitol fermentation is not an invariable marker. The occurrence of verotoxin production in serotypes other than 0157 in haemorrhagic colitis and haemolytic uraemic syndrome suggests that there is no obvious reason why the absence of sorbitol fermentation should be linked genetically to verotoxin production. Direct detection of verotoxin producing E coli by the use of DNA probes is being developed. It is more sensitive, but is not generally available in diagnostic laboratories. Until then, our study has shown that sorbitol-MacConkey agar coupled with agglutination is helpful.
Haldane et al recommended the inclusion of lysine and ornithine decarboxylation with sorbitol non-fermentation as an improved biochemical screen.'t They found that all of their 37 verotoxin producing E coli 0157 produced both lysine and ornithine decarboxylase. In our study six of seven strains produced lysine and ornithine decarboxylase, but one strain was negative for both. Isolates of verotoxin producing E coli have also been reported to be characteristically raffinose fermenters and I-glucuronidase nonproducers. 25 26 We believe that these additional biochemical variables are of less use than confirmation of serotype and verotoxin production, both of which are available to laboratories with access to cell culture.
Slide and tube agglutination techniques seem to be equally reliable. Slide agglutination was quick and easy to perform while tube agglutination was more time consuming and a result took a day longer. Isolates ofE coli can be screened by slide agglutination Detection of verotoxin producing E coli 83 from the sorbitol-MacConkey medium, with positive or equivocal results being confirmed by tube agglutination.
All of our isolates of E coli 0157 produced verotoxin. The cytopathic effect of verotoxin was easy to distinguish and differed clearly from that ofthe heat labile toxin of E coli and the cytotoxin of Clostridium difficile. The cytopathic effect was observed after 24 hours' incubation so that it may not be necessary to incubate for three days. Our laboratory method for detection ofverotoxin production was specific, with all positive results being confirmed by the reference laboratory.
Karmali et al detected verotoxin in all of five faecal samples that yielded verotoxin producing E coli and in two samples from which no verotoxin producing E coli were isolated.7 Similarly, Krishnan et al found verotoxin in 17 of 18 cases in which E coli 0157 were isolated and in an additional seven samples from which no verotoxin producing E coli were isolated.25 In our study, however, only two of seven samples which yielded verotoxin producing E coli 0157 showed faecal verotoxin. This may have been due to an insensitive technique or to storage of unbuffered faeces. Detection of verotoxin in faeces seems to be of limited use until this technique is further validated and specific neutralising antitoxin becomes available.
Four of the E coli 0157 isolates were from the 80 patients who presented with bloodstained diarrhoea. No evidence of bloodstained diarrhoea was found in the remaining three patients: failure by clinicians to record that diarrhoea was bloodstained, lowwnumbers of organisms present, or samples being submitted more than one week after onset of the illness may have contributed to this.'3 14 1725 Thus these three cases would have been missed if the decision to culture for E coli 0157 had rested on clinical and microscopic findings alone. Until the epidemiology of and familiarity with this condition increases, it seems unwise to restrict examination of faeces for this pathogen on the basis of clinical history or microscopy.
It is important that clinical microbiology laboratories are able to isolate and identify this new pathogen because of the implications for diagnosis of haemorrhagic colitis and clinical management, including surgery. DNA probes have been developed for the detection of verotoxin but are not available to most clinical laboratories. The more sensitive technique of application of DNA probes to cultures resulted in a greater detection of verotoxin producing E coli in the trial of Smith et al.24 Screening for NSF organisms followed by slide agglutination seems to be a simple, inexpensive and sensitive alternative. It can easily be incorporated into routine methods on all faecal samples, particularly as commercial supplies of media and antisera are now available. Detection of verotoxin production may then be performed for confirmation if Vero cell cultures are available. We thank Oxoid Ltd for the supply of sorbitolMacConkey medium and Wellcome Diagnostics for the 0157 antiserum.
